This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Shebin Althaf, Manoj Khanal, Anita Rawat, et.al./Devic’s Disease: The Confusing CNS Disease /Indian J Emerg Med
2023;9(3):107 – 109.
Timeline
Received : March 15, 2023
Accepted : April 20, 2023
Published : May 09, 2023
Abstract
Neuromyelitis optica spectrum is order (NMOSD) is a rare auto-antibody mediated disease of the central nervous system involving the central nervous system. The symptoms should alert the clinician to the diagnosis. Prompt diagnosis in the emergency department plays a crucial role as delay in diagnosis and initiation of management will lead to increased chances of morbidity and mortality. Approximately 80% of NMO patients have auto-antibodies against aquaporin-4, a water channel expressed on astrocytes. In this case report, we discuss a patient with NMO disease, the diagnosis and its management.
References
1. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10(1):8.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.
3. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(13):1273–7.
4. Flanagan EP, Weinshenker BG, Krecke KN, Chen S, Toledo SA, Lucchinetti CF, et al. Short myelitis lesions in aquaporin-4-IgG–positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–7.
5. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9.
6. Kim HJ, Friedemann P, Lana-Peixoto MA, Misu T, Weinshenker BG, Wingerchuk DM, et al. MRI characteristics of neuromyelitis optica spectrum disorder. Neurology. 2015;84(11):1165–73.
7. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206–16.
8. Palace J, Leite I, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol. 2012;12(4):209–14.
9. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J. 2011;18(1):113–5.
Data Sharing Statement
There are no additional data available. All raw data and code are available upon request.
Funding
This research received no funding.
Author Contributions
All authors contributed significantly to the work and approve its publication.
Ethics Declaration
This article does not involve any human or animal subjects, and therefore does not require ethics approval.
Acknowledgements
Information not provided.
Conflicts of Interest
The authors report no conflicts of interest in this work.
About this article
Cite this article
Shebin Althaf, Manoj Khanal, Anita Rawat, et.al./Devic’s Disease: The Confusing CNS Disease /Indian J Emerg Med
2023;9(3):107 – 109.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.